Sernova Corp T.SVA

New base $2

[MustangSalley]

Well we have to see what interim news on trial is on Monday . Market is expecting at least two or hopefully three insulin independent patients .  Hopefully share price bases here, again the fact competition is failing and the clinical results are holding are factors in the share price .

The real catalyst will be any pharma deal of substance .

@Ripix ..... now why would anybody sell just before a major catalyst ?  Didn't you sell a whole,e bunch before at 4o cents before news came out before it took off to $1.30?  

Werent you crying managemen5 wasn't buying any stock for Bitk? 

MS

[Metalsguy1]

Good points MS. I am happy to see a reasonable rise to genius over 2. At the same time, O am wondering whether management is actually going to take advantage of it and get news out that will keep it moving or...once again shoot themselves in the foot. I think the latter is less likely since they just handed out DSUs like Christmas candy at an orphanage.

[Mercuryfilling1]

Quite right…jolly good, Metals, old chap. Spot on. Erudite and concise, as ever old boy.   I must say, dear fellow, that “old maid underwear” reference was a nice wink to your special type of indulgence, but mums the word on that account - say no more.  Well done lad. COME ON retail (and those who are or should be institutionalized), let 'er rip. Dr. W may be about to release the

[Metalsguy1]

MercuryFilling is once again talking to hear his head rattle.

[rixpix]

Come on, Mustang, Admit it. You enjoy following me. I've told you a million times, I don't cry over stocks.  You enjoy trying to belittle mock and insult me, even going as far as posting false statements to make yourself look superior. I never sold a single share @ 40 cents, like you say, sold 39,500 @ 71 cents a year ago, and still hold 200 thousand, but you know that. I've

[MustangSalley]

Rix, My objective is to get a return on my investment.  I have no need to ridicule you but I do find you the most annoying poster . You brought up $2 thing today. I just responded . Catalysts have  the ability to really change the outlook of the company versus a year ago . I stand corrected  it was 70 cents that yiu sold and it went up to 2.80 before returning to 1.20. What

[MoneyMouth]

I think you are being a little too conservative. If they were to announce another insulin independent patient that would be even bigger news than last january because it shows it is repeatable and not a one off. It might seem insignificant to all of us who have been talking about it for a year, but there are still many many investors and new money coming in if the news is that big

[Metalsguy1]

MM I would agree with you except for one small caveat. If the only insulin independent patients are those with a portal vein top up the market response might be tempered.

[MoneyMouth]

I've pondered that same thing but have come to the conculsion that the reaction will not be tempered on account of the fact that 1) unless an investor is in the know, they don't know what a portal vein injection is and all they see is "Insulin Independent" And 2) it is still significant that the pouch with, quote, "a marginal dose of islets" in the portal vein is

[MustangSalley]

Mouth, You make a very valid point . Even with a single top up, insulin independence is wuite remarkable . How many patients would go for that ?  it is a significant milestone in itself.   If you look at the recent December presentation , take careful note that they are now manufacturing several sizes of the pouch according to Gmp specs. This is significant because it means they

[Redbaron2211]

Agree. As we hone in dosing, the amount of top up needed should be less, and it's important to note insulin production before top up is already significant. With cells surviving long term and the pouch showing safety and efficacy in multiple patients, this is without a doubt the best option for multiple indications.  We already know this tech was reaching 1B+ valuations preclinical. 

[BioTeck]

Read the presentation reddy. The insulin reduction on the one reported patient isn't that much and not significant. Only the quick acting insulin but that could be reduced by dietary changes as the patient has also lost significant weight.

[Redbaron2211]

Bio Tresiba the long acting insulin went down from 14U to 8U, that's significant, no other peers have come close.  You haven't been this concerned about the SP going up since last year, must mean there is potential for one hell of a run.    

[BioTeck]

The one significant point that is being missed is that with a marginal islet dose (which currently comes from cadavers), a single doner may be able to help a few patients who have the pouch. I think the Edmonton protocol might require 2 pacreata per patient. I still think the price will come down on news. Hype right now is huge and there are lots of people waiting to take profits. Once the selling

[MustangSalley]

Bioteck, Sva is working on to get stem cell line that would provide unlimited source of cells. Again there would have to be a trial to prove the stem cells are safe in conjunction with conformal coding . Still ways alway from popping the champagne .  If results are not stellar, news will be sold on Monday . Selfie will be selling and skimming the profit while he's pumping like overdr8ve

[rixpix]

You're right Mustang. It's no one's business when you sell, or when anyone sells for that matter. But I never told you to sell at $2. It's YOU that said you'd sell at 2 when/if it gets there and you'd stop posting here. Your words, not mine. Like I said, I've never told anyone to sell when they're not happy with the stock or it's directors. (Unlike you) As for